Overcoming Resistance to EGFR Inhibitors in EGFR-Mutant NSCLC (Volume 19) (Cancer Sensitizing Agents for Chemotherapy, Volume 19) - Image 1

£114.06

Academic Press Overcoming Resistance to EGFR Inhibitors in EGFR-Mutant NSCLC (Volume 19) (Cancer Sensitizing Agents for Chemotherapy, Volume 19)

Name: Overcoming Resistance to EGFR Inhibitors in EGFR-Mutant NSCLC (Volume 19) (Cancer Sensitizing Agents for Chemotherapy, Volume 19)
Brand: Academic Press
Price: 114.06 GBP
Availability: InStock

Oncology

It has never been this cheap. We have no record of a lower price.

£114 today · cheaper than every other day in the last 3 months

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 55 days · 55 data points (no recent data)

Historical

Generating forecast…

Price Distribution

Price distribution over 55 days • 1 price levels

Days at Price

Price Analysis

Most common price: £114 (55 days, 100.0%)

Price range: £114 - £114

Price levels: 1 different prices over 55 days

Description

Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC presents updated information on how EGFR mutant lung cancers evolve to evade EGFR inhibitors, clinical strategies that identify these mechanisms, and how to implement newer therapeutic strategies to combat resistance and improve patient survival. As resistance to EGFR inhibitors is often through re-activation of MEK/ERK and PI3K pathways, or through loss of cell death responses, there is much overlap with resistance to targeted therapies in other paradigms, such as BRAF inhibitors in BRAF mutant melanoma, and HER2 inhibitors in HER2 amplified breast cancer. This book is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field who are interested in promising treatments for lung cancer. Presents historical context on how NSCLC and SCLC has been treated, with an emphasis on NSCLC and how the concept of EGFR inhibitors has been implemented Discusses critical resistant mechanisms seen in the clinic to 1st, 2nd and 3rd generation EGFR inhibitors Encompasses the current state of affairs in clinical trials to address resistance

Product Specifications

Brand: Academic Press
Format: hardcover
ASIN: 0128228334
Category: Books > Subjects > Health, Family & Lifestyle > Medical & Healthcare Practitioners > Internal Medicine > Diseases & Disorders > Oncology
Domain: Amazon UK
Release Date: 05 February 2023
Listed Since: 01 February 2020

Barcode

No barcode data available

Academic Press Overcoming Resistance to EGFR Inhibitors in EGFR-Mutant NSCLC (Volume 19) (Cancer Sensitizing Agents for Chemotherapy, Volume 19)

It has never been this cheap. We have no record of a lower price.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Barcode

Similar Products You Might Like

Springer - Lung Cancer: Treatment and Research: 170 Book

Cancer Drug Resistance: Overviews and Methods: 1395 (Methods in Molecular Biology, 1395)

Targeted Therapies in Oncology

Springer - Signaling Pathways and Molecular Mediators in Metastasis

Improving the Therapeutic Ratio in Head and Neck Cancer (Volume 6) (Cancer Sensitizing Agents for Chemotherapy, Volume 6)

Advances in Respiratory Cancerogenesis: 911 (Advances in Experimental Medicine and Biology, 911)

Cancer Chemotherapy: Basic Science to the Clinic

Cancer Biology and Therapeutics

Advances in Clinical Science: 878 (Advances in Experimental Medicine and Biology, 878)

Advances in Cancer Research: 77: Volume 77

Lung Cancer (MD Anderson Cancer Care Series)

Overcoming Drug Resistance in Gynecologic Cancers (Volume 17) (Cancer Sensitizing Agents for Chemotherapy, Volume 17)

The Molecular Basis of Human Cancer

Wiley Anticancer Therapeutics - Oncology Drug Design Book

Molecular Oncology: Underlying Mechanisms and Translational Advancements

The Bethesda Handbook of Clinical Oncology

Small Molecules for Cancer Treatment

Combination Cancer Therapy: Modulators and Potentiators (Cancer Drug Discovery and Development)

Drug Resistance in Cancer Cells

The Story of Hydra: Portrait of Cancer as a Stem-Cell Disease

New Trends in the Molecular and Biological Basis for Clinical Oncology

Oxford Textbook of Cancer Biology - Oxford University Press

A Beginner's Guide to Targeted Cancer Treatments and Cancer Immunotherapy

Biotargets of Cancer in Current Clinical Practice (Current Clinical Pathology)